Kyntra Bio
KYNB
187 hedge funds and large institutions have $2.66B invested in Kyntra Bio in 2017 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 68 reducing their positions, and 23 closing their positions.
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
3% more funds holding
Funds holding: 182 → 187 (+5)
3% more capital invested
Capital invested by funds: $2.58B → $2.66B (+$82.3M)
0.05% more ownership
Funds ownership: 2.42% → 2.47% (+0.05%)
7% less call options, than puts
Call options by funds: $21.9M | Put options by funds: $23.5M
10% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 68
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$35.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$32.5M |
| 3 |
Janus Henderson Group
London,
|
+$30.4M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$28M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$12.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.5M |
| 3 |
TA
Teachers Advisors
New York
|
-$10.3M |
| 4 |
BA
Boston Advisors
Boston,
Massachusetts
|
-$9.46M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$9.21M |
KYNB Hedge Fund Activity: Q4 2017 in Review
187 of the 4,418 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2017, worth a combined $2.66B — up 3.2% from $2.58B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KYNB positions and 23 closed out — a net gain of 5 holders — while 61 added to existing stakes and 68 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $35.6M. The largest seller was Nationwide Fund Advisors, exiting entirely with an estimated $12.6M sold.
- 187 institutional investors held Kyntra Bio (KYNB) as of Q4 2017, up from 182 in Q3 2017.
- Funds reported $2.66B of Kyntra Bio stock for Q4 2017, up 3.2% quarter-over-quarter.
- 28 funds opened new Kyntra Bio positions in Q4 2017 and 23 closed out, a net change of +5 holders.
- The largest Kyntra Bio buyer in Q4 2017 was First Trust Advisors, an estimated $35.6M added.
- The largest Kyntra Bio seller in Q4 2017 was Nationwide Fund Advisors, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2017.